期刊
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
卷 60, 期 4, 页码 265-268出版社
SPRINGER
DOI: 10.1007/s00228-004-0763-y
关键词
fluticasone propionate; mometasone furoate; nasal bioavailability
Objectives. To compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics. Methods. Twelve healthy subjects completed this three-way, cross-over study. They received FPANS (50 mug/spray), MFANS (50 mug/spray) or placebo ANS, eight sprays per nostril every 8 h for 4 days. Cortisol measurements were made at baseline and day 4. FP and MF plasma concentrations were also measured on day 4. Results. MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h). Despite the use of high doses, necessary to generate adequate pharmacokinetic data, only minor reductions in cortisol parameters were found, with no difference between FPANS and MFANS. Conclusions. FP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen. It is therefore unlikely that therapeutic doses of intranasal FP or MF will produce dissimilar or significant degrees of systemic exposure or systemic effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据